Although many miRNAs are reported to be involved in tumor formation and progression, the effect of miR-219a-5p on breast cancer metastasis is not well-known. The aim of this study is to investigate the effect of miR-219a-5p on the migratory ability and epithelial-mesenchymal transition (EMT) of breast cancer cells. First, miR-219a-5p was found to be highly expressed in low-invasive breast cancer MCF-7 cells, but lowly expressed in high-invasive breast cancer MDA-MB-231 cells. Wound scratch assay and transwell assay showed that miR-219a-5p inhibited the migratory ability of MDA-MB-231 cells. miR-219a-5p also suppressed the cellular EMT, confirmed by suppressing the expression of mesenchymal markers vimentin and N-cadherin and increasing the expression of epithelial marker E-cadherin. Using the epithelial-mesenchymal-epithelial model in MCF-7 cells, we confirmed that the level of miR-219a-5p was highly expressed in epithelial-type cells and lowly expressed in mesenchymal-type cells. Importantly, we identified myocardin-related transcription factor A (MRTF-A) as a novel potential target gene of miR-219a-5p. Overexpression of miR-219a-5p in MDA-MB-231 cells could inhibit the expression of MRTF-A as revealed by real-time PCR and western blot analysis. miR-219a-5p inhibited the transcription of MRTF-A by targeting the 3′UTR of MRTF-A, which was confirmed by wild-type or mutant MRTF-A 3′UTR luciferase reporter system. Furthermore, knockdown of MRTF-A using siRNA for MRTF-A could depress breast cell migration. In conclusion, our present study revealed the tumor suppressive role of miR-219a-5p in regulating breast cancer migration by targeting MRTF-A, suggesting that miR-219a-5p might be a therapeutic target in breast cancer through regulating EMT.
Introduction
Cancer metastasis is responsible for more than 90% of cancerrelated deaths [1] . The initial step of migration and progression is substantially dependent on epithelial-mesenchymal transition (EMT), which is characterized by specific morphogenetic changes [2] . EMT consists of a complex series of events, the symbol of which is the loss of epithelial cell-cell and cell-basement membrane attachments, and the gain of mesenchymal-like morphology, accompanied by gene expression alternations, including the decreased expression of epithelial markers (such as E-cadherin) and the increased expression of mesenchymal markers (such as N-cadherin and vimentin) [3, 4] . EMT allows tumor cells to become motile and invasive, and leave their primary sites [5] . EMT can be triggered by different signaling molecules, such as transforming growth factor-β (TGF-β), epidermal growth factor, hepatocyte growth factor, bone morphpgenetic proteins, Wnt, and Notch signaling, among which TGF-β is a major inducer of EMT [6, 7] .
MicroRNAs (miRNAs) are small, noncoding, highly conserved RNA molecules, approximately 22 nucleotides (nt) long, having the capacity to regulate key biological processes such as cellular proliferation, differentiation, and migration [8] . They repress target gene expression by binding to specific sequences named miRNA-response elements (MREs) in the 3′ untranslated region (3′UTR) of target mRNAs [9] , triggering their target mRNA degradation or translation inhibition [10] . Emerging evidence has recently shown that numbers of miRNAs play important roles in human cancer cell survival, apoptosis, and migration [11, 12] . miR-219a-5p locates on chromosome 6 (MI0000296) and is specifically expressed in the brain [13] . It plays an important role in oligodendrocyte differentiation, and neural stem cell proliferation [14] [15] [16] [17] . miR-219a-5p has been reported to inhibit several cancer cells such as papillary thyroid carcinoma cells, glioblastoma cells, and D283-MED medulloblastoma cells [18] [19] [20] . Breast cancer causes many deaths in women and its important characteristics are metastatic potential and fast growth [21] . However, whether miR-219a-5p could inhibit migration of breast cancer is unclear.
Myocardin-related transcription factor A (MRTF-A) is a unique co-activator of serum-response factor (SRF), which translocates into the nucleus where it interacts with SRF to bind to CArG-box (CC (A/ T) 6 GG) in the promoters of genes to activate transcription [22] [23] [24] . Rho/MRTF-A signaling pathway has been reported to play an important role in cancer metastasis [25, 26] . Recently, our studies revealed that MRTF-A can up-regulate the transcription of migration-related genes and promote the migration of breast cancer cells by cooperating with other factors including STAT3, p300, and SMYD3 [27] [28] [29] .
Bioinformatics analysis shows that MRTF-A was a potential target gene of miR-219a-5p. In this present study, using the epithelialmesenchymal-epithelial model, we explored the role of miR-219a-5p in breast cancer cell migration and studied the mechanism underlying its anti-tumor effect by suppressing tumor cell migration.
Materials and Methods

Cell lines, reagents, and transfection
Human breast cancer cell lines MDA-MB-231, MCF-7, human liver cancer cell line HepG2, human umbilical vein endothelial cells (HUVECs) and rat brain glioma cell line C6 were obtained from American Type Culture Collection (ATCC, Manassas, USA). These cells were grown in Dulbecco's modified Eagle's medium (Gibco, Carlsbad, USA) supplemented with 10% fetal bovine serum (FBS; Sijiqing, Hangzhou, China) and 1% penicillin-streptomycinamphotericin B (Sangon Biotech, Shanghai, China) at 37°C in a humidified incubator (Thermo Forma, New York, USA) with 5% CO 2 . Human breast cancer cell line MCF-10A (ATCC) was cultured in DMEM supplemented with 5% horse serum (Sijiqing), 20 ng/ml epidermal growth factor (EGF; Propotech, Rocky Hill, USA), 0.5 μg/ ml hydrocortisone (Solarbio, Beijing, China), 100 ng/ml cholera toxin (Sigma, St Louis, USA), 10 μg/ml insulin (Sigma), and 1% penicillin-streptomycin-amphotericin B (Sangon Biotech).
miR-219a-5p mimics and negative control miRNA mimics were purchased from Qiagen (Hilden, Germany). The specific siRNA targeting MRTF-A was synthesized by Invitrogen (Carlsbad, USA). miR219a-5p inhibitor and control were purchased from Ribobio (Guangzhou, China). The sequences of human siMRTF-A were: sense strand, 5′-GAAUGUGCUACAGUUGAAAdTdT-3′; and antisense strand, 5′-UUUCAACUGUAGCACAUUCdTdT-3′. The sequences of the control siRNA were: sense strand, 5′-UUCUUCGAACGUGUCAC GUTT-3′; and antisense strand, 5′-ACGUGACACGUUCGGAGAA TT-3′. miR-219a-5p mimics and siRNA targeting MRTF-A were transfected into cells using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions.
RNA extraction and real-time PCR
Total RNA from cultured cells was extracted using Trizol reagent (Invitrogen), and small RNA was extracted using miRcute miRNA isolation kit (TIANGEN, Beijing, China). All RNA was reversetranscribed into cDNA with the Reverse Transcriptase M-MLV (Invitrogen) according to the manufacturer's instructions. The reverse transcription primer of total RNA was oligo(dT), and the reverse transcription primer of U6 and miR-219a-5p respectively was 5′-CTCGCTTCGGCAGCACA-3′ and 5′-GTCGTATCCAGT GCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACAGAA TT-3′. The real-time PCR analysis was performed with Applied Biosystems StepOne™ System (Applied Biosystems, Foster City, USA). The thermal cycle profile was as follows: denaturation for 2 min at 95°C, annealing for 1 min at 55°C depended on the primers used, and extension for 30 s at 60°C. Each PCR reaction was performed for 40 cycles. Data were shown as relative expression level after being normalized by glyceral-dehyde-3-phosphate (GA PDH) or U6. The PCR primer sequences are listed in Table 1 .
MTT assay
MDA-MB-231 cells were seeded in 96-well plates and cultured for 24 h, and then cells were transfected with miR-219a-5p mimics (5 nM) or miRNA negative control (5 nM). About 12 h or 24 h later, 20 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution in concentration of 5 mg/ml was added into each well, then the cells were cultured in an incubator for 4 h. Finally, 100 μl of DMSO was added into each well and the absorbance of each well was measured at 490 nm/570 nm with an automatic microplate reader. Experiments were repeated at least three times.
Transwell assay
Transwell assay was performed using 8-μm pore polycarbonate membrane transwell chambers (Corning Co, Corning, USA). MDA-MB-231 cells were transfected with miRNA mimics or siRNA. About 6 h after transfection, cells were resuspended in RPMI-1640 without FBS. Cells (5 × 10 5 ) were cultured in the top chamber of the transwell chambers, and 500 μl RPMI-1640 with 10% FBS was added to the bottom chamber. Cells were allowed to migrate for 16 h and then cells on the top of the membrane were scraped off. Migrated cells were fixed with 4% formaldehyde and stained with 4′,6-diamidino-2-phenylindole (DAPI). Cells were counted under a microscope in five different fields in a well. Experiments were repeated at least three times.
Wound-healing assay
) were seeded in 6-well plates. Six hours after transfection, wounding was induced by scratching the cell monolayer with a 10-μl plastic pipette tip, and then the cells were cultured at 37°C in a 5% CO 2 incubator chamber. Pictures were acquired at 0, 12, and 24 h using a microscope. Experiments were repeated three to five times.
Western blot analysis
Preparation of total cell extracts and analysis of western blots with the appropriate antibodies were performed as described previously [22] . The primary antibodies used included mouse anti-vimentin antibody (Santa Cruz, Santa Cruz, USA), mouse anti-E-cadherin antibody (Santa Cruz), mouse anti-GAPDH antibody (Santa Cruz), rabbit anti-N-cadherin antibody (Santa Cruz) and rabbit anti-MRTF-A antibody (Protect, Taipei, China) antibodies. The secondary antibodies were IRDye ® 800CW anti-rabbit secondary antibody and IRDye ® 680 anti-mouse secondary antibody (Li-COR, Lincoln, USA). The specific proteins were analyzed by Odyssey™ Infrared Imaging System (Gene, Hong Kong, China) and equal loading of the protein samples were normalized by GAPDH expression.
Luciferase reporter assay
The human MRTF-A 3′UTR was subcloned into plasmid pmir-GLO by PCR using the following primers: forward primer 5′-GGGGAG CTCGCTTGTAGCTCTCTGGCTCAAGAC-3′; and reverse primer 5′-AGGCTCGAGTGTGAGAGTAGGATGGGAGGGAGTTG-3′. The human MRTF-A 3′UTR-mut luciferase reporter plasmid was constructed using the following primers: forward primer 5′-CCACATGG TTGTGAGTCTTTGAGGCTGCAGCCCCTGCTTTTTC-3′; and reverse primer 5′-GAAAAAGCAGGGGCTGCAGCCTCAAAGACTCACAA CCATGTGG-3′.
MDA-MB-231 cells were seeded into 24-well plates one day before transfection. 3′UTR reporter construct (MRTF-A 3′UTR or MRTF-A 3′UTR-mut; 500 ng) and miRNA negative control or miR-219a-5p mimics were transfected into MDA-MB-231 cells by Lipofectammine 2000 (Invitrogen) at a final concentration of 1 μg per well in 24-well plates. After 24 h, luciferase activity was measured with a Synergy™ 4 (Bioteck, Vermont, USA). Transfection efficiencies were normalized by total protein concentrations of each sample.
Statistical analysis
Data were presented as the mean ± standard error (SE) and accompanied by the number of experiments performed independently. Data were analyzed by t-test. P < 0.05 was considered statistically significant.
Results
Expression of miR-219a-5p in different cell lines miR-219a-5p is a brain-specific microRNA and highly homologous in three mammalian species, including human, mouse and rat (Fig. 1A) . The expression of miR-219a-5p was tested in several cell lines, including normal breast human mammary epithelial cell line MCF-10A, breast cancer MCF-7 and MDA-MB-231, cervical cancer Hela and live cancer HepG2 cells by real-time PCR. Rat glioma cell line C6 was used as the positive control. The results showed that the expression of miR-219a-5p was remarkably higher in C6 cells than in other cell lines (Fig. 1B) . Compared with non-cancerous human breast epithelial MCF-10A cells, the expression of miR-219a-5p was slightly but not significantly decreased in human breast cancer MCF-7 cells. However, significantly lower expression of miR-219a-5p was observed in MDA-MB-231 cells in comparison with MCF-10A cells. miR-219a-5p expression was higher in low-metastasis MCF-7 cells than in high-metastasis MDA-MB-231 cells. Of note, MCF-7 cell line was low-metastasis and had an epithelium-like morphology, whereas MDA-MB-231 cell line was highly metastasis and had a spindle-shaped, fibroblastic mesenchymal phenotype [30, 31] . Therefore, we hypothesized that the level of miR-219a-5p might be associated with the metastasis of breast cells, and miR-219a-5p might inhibit the migration of breast cells. Table 1 . Sequence of primers used in real-time PCR
Gene
Primer sequence (5′→3′) miR-219a-5p inhibits MDA-MB-231 cell metastasis and EMT
To confirm the effect of miR-219a-5p on MDA-MB-231 cell proliferation, MTT assay was performed in high-metastasis MDA-MB-231 cells transfected with miR-219a-5p or control miRNA. miR-219a-5p had no obvious effect on MDA-MB-231 cell viability at 24 h ( Fig. 2A) . Next, to investigate whether miR-219a-5p could inhibit the migration of breast cancer cells, miR-219a-5p was transfected into MDA-MB-231 cells and then transwell assay and wound-healing assay were performed. Six hours after transfection with miR-219a-5p mimics, cells were seeded into the chamber and the migrated cells were counted at 16 h of migration. miR-219a-5p significantly decreased the number of cells migrating into lower chamber (about >30% decrease; Fig. 2B ). Six hours after transfection with miR-219a-5p mimics, MDA-MB-231 cells were scratched with a 10-μl plastic pipette tip, and then pictures were acquired at 0, 12, and 24 h using a microscope. Compared with control groups, cell mobility was significantly reduced in the cells transfected with miR-219a-5p at 12 and 24 h (Fig. 2C) . These date revealed that miR-219a-5p could inhibit MDA-MB-231 cell migration.
Since the initial step of migration progression is substantially dependent on EMT, we further investigated whether miR-219a-5p could inhibit the migration progress in MDA-MB-231 cells by suppressing EMT. It is well-known that EMT is characterized by decreased expressions of epithelial cell adhesion markers (such as E-cadherin) and increased expressions of mesenchymal markers (such as N-cadherin and vimentin) [3, 4] . It was found that overexpression of miR-219a-5p dramatically down-regulated the expression of N-cadherin and vimentin and up-regulated the expression of E-cadherin in MDA-MB-231 cells (Fig. 2D,E) . These data indicated that miR-219a-5p could inhibit high-metastasis breast cancer cell MDA-MB-231 migration and EMT.
EMT-MET model is established in MCF-7 cells
TGF-β signal pathway plays an essential role in metastatic spread of cancer cells, such as migration, and EMT [32] . TGF-β, as a critical inducer of EMT, promotes the process of EMT via repressing the Figure 2 . miR-219a-5p inhibits MDA-MB-231 cell migration and EMT (A) miR-219a-5p had no obvious effect on MDA-MB-231 cell viability at 24 h. miR-219a-5p was transfected into MDA-MB-231 cells, and then transwell assay (B) and wound-healing assay (C) were performed. miR-219a-5p was transfected into MDA-MB-231 cells and the expression of vimentin, N-cadherin and E-cadherin were detected by real-time PCR (D) and western blot analysis (E). *P < 0.05, **P < 0.01, ***P < 0.001. Experiments were repeated three times (n = 3). expression of epithelial markers and activating the expression of mesenchymal markers. TGF-β has been reported to induce EMT in MCF-7 and MDA-MB-231 cells [32, 33] . MCF-7 cells were incubated with 5 ng/ml TGF-β for 24 h, fresh medium was replaced to remove TGF-β, and then the cells were subsequently cultured for another 24 h. During this progress, the expression of mesenchymal marker vimentin and Ncadherin and epithelial marker E-cadherin was detected by real-time PCR and western blot analysis. As shown in Fig. 3A ,B, addition of TGF-β increased the expression of vimentin and N-cadherin and decreased the expression of E-cadherin in MCF-7 cells, while removal of TGF-β reduced the level of vimentin and N-cadherin and increased the level of E-cadherin. The increase of the expression of mesenchymal markers and the decrease of the expression of epithelial marker in TGF-β-treated MCF-7 cells during the first 24 h suggested the occurrence of epithelial-mesenchymal transition. Importantly, epithelial to mesenchymal transition may be reversible. Thus, mesenchymal to epithelial transition occurred due to removal of TGF-β during the subsequent 24 h, confirmed by gain of epithelial cell marker and loss of mesenchymal cell markers. These data indicated that EMT-MET model was successfully constructed in MCF-7 cells.
The expression of miR-219a-5p and MRTF-A in the EMT-MET model
To investigate the role of miR-219a-5p in EMT and MET, the level of miR-219a-5p was detected in the EMT-MET model. As shown in Fig. 4A , the level of miR-219a-5p was decreased during the first EMT process and then increased during the subsequent MET process.
MRTF-A was previously found to be involved in EMT in cancer cell lines. To explore the potential relationship between miR-219a-5p and MRTF-A, we detected the expression of MRTF-A in the EMT-MET model by real-time PCR and western blot analysis. Contrary to the expression of miR-219a-5p during the EMT-MET process, the expression of MRTF-A was up-regulated during the first EMT process and then down-regulated during the subsequent MET process (Fig. 4B,C) .
MRTF-A is the direct target of miR-219a-5p
By bioinformatics analysis, we found that MRTF-A is a potential target gene of miR-219a-5p. We first explored whether overexpression of miR-219a-5p was associated with the inhibition of MRTF-A. To confirm this hypothesis, MDA-MB-231 cells were transfected with miR-219a-5p and then the expression of MRTF-A was tested by realtime PCR and western blot analysis. As shown in Fig. 5A ,B, overexpression of miR-219a-5p could significantly inhibit the mRNA level and protein level of MRTF-A.
By bioinformatics analysis, we identified a potential binding site of miR-219a-5p in the 3′UTR of MRTF-A (Fig. 5C) . To demonstrate whether miR-219a-5p can inhibit the expression of MRTF-A by interacting with its target sequence in the 3′UTR of MRTF-A, we cloned the 3′UTR of human MRTF-A containing the predicted binding sites of miR-219a-5p into the pmirGLO vector. In addition, the human MRTF-A 3′UTR-mut luciferase reporter plasmid was also constructed. For MRTF-A 3′UTR-mut luciferase reporter plasmid, Figure 3 . EMT-MET model is established in MCF-7 cells MCF-7 cells were incubated with 5 ng/ml TGF-β for 24 h, fresh medium was replaced to remove TGF-β, and then the cells were cultured for another 24 h. During this progress, the expression of mesenchymal marker vimentin and N-cadherin and epithelial marker E-cadherin were detected by real-time PCR (A) and western blot analysis (B). *P < 0.05, **P < 0.01. Experiments were repeated three times (n = 3). the sequence 5′-GACAATCA-3′, which matched with miR-219a-5p, was changed to 5′-TGAGGCTG-3′ (Fig. 5C) . Transient cotransfection of miR-219a-5p mimics with the reporter plasmid in MDA-MB-231 cells significantly reduced luciferase activity, compared with transfection of the negative control mimics (Fig. 5D) . The inhibitory effect of miR-219s-5p was reversed when the binding site of miR-219a-5p within the 3′UTR of MRTF-A was mutated. These results revealed that miR-219a-5p could directly target MRTF-A by binding to the sequence within MRTF-A 3′UTR.
MRTF-A promotes MDA-MB-231 cell metastasis and EMT
To confirm the positive effect of MRTF-A on breast cancer cell metastasis, siRNA targeting MRTF-A was transfected to MDA-MB-231 cells, and then cell migratory ability was measured by woundhealing and transwell assay. Western blot analysis showed that siMRTF-A transfetion decreased the expression of MRTF-A in MDA-MB-231 cells (Fig. 6A) . Twenty hours after transfection with siMRTF-A, cells were scratched with a10-μl plastic pipette tip, and then pictures were acquired after 12 h. The data revealed that the rate of wound closure in the cells transfected with siMRTF-A was 60.49% ± 8.13%, while the rate of wound closure in the control group was 87.08% ± 11.76%, which suggested that decreased expression of MRTF-A resulted in the inhibition of migration (Fig. 6B) . Similar results were observed in the transwell assay. Compared with the control group, the migration rate of MDA-MB-231 cells transfected with siMRTF-A was significantly reduced (Fig. 6C) . These data demonstrated that knockdown of MRTF-A could inhibit the migration ability of MDA-MB-231 cells.
To further investigate the role of MRTF-A in EMT, the expression of mesenchymal markers and epithelial marker were tested by real-time PCR and western blot analysis in siMRTF-A-transfected MDA-MB-231 cells (Fig. 6D,E) . Knockdown of MRTF-A led to Figure 5 . MRTF-A is a potential target of miR-219a-5p MDA-MB-231 cells were transfected with miR-219a-5p, and then the expression of MRTF-A was tested by real-time PCR (A) and western blot analysis (B). (C) The human MRTF-A 3′UTR luciferase reporter plasmids containing the predicted binding sites (wild-type or mutant) for miR-219a-5p were constructed. For MRTF-A 3′ UTR-mut luciferase reporter plasmid, the sequence GACAATCA, which matched with miR-219a-5p, was changed to TGAGGCTG. (D) MDA-MB-231 cells were transiently co-transfected with miR-219a-5p mimics with the reporter plasmids, and then luciferase activity assay was performed. *P < 0.05, **P < 0.01. Experiments were repeated three times (n = 3). increased expression of epithelial marker E-cadherin and decreased expression of mesenchymal marker vimentin. No obvious change was observed in the expression of N-cadherin (Fig. 6D,E) . These data showed that MRTF-A could promote EMT in MDA-MB-231 cells.
miR-219a-5p inhibits breast cancer cell migration and EMT by targeting MRTF-A miR-219a-5p mimics and MRTF-A overexpression plasmid were co-transfected into breast cancer MDA-MB-231 cells, the expression of epithelial and mesenchymal markers were detected by real-time PCR and western blot analysis, and cellular migration assay was evaluated by wound-healing and transwell assay. As predicted, miR219a-5p dramatically down-regulated the level of N-cadherin and vimentin, and up-regulated the level of E-cadherin in MDA-MB-231 cells, while overexpression of MRTF-A recovered the expression of mesenchymal markers and inhibited the increase of epithelial marker in response to miR-219a-5p (Fig. 7A,B) . Wound-healing and transwell assay also showed that MRTF-A could rescue the inhibitory effect of miR-219a-5p on the migration of MDA-MB-231 cells (Fig. 7C,D) . These results suggested that miR-219a-5p could inhibit breast cancer cell migration and epithelial-mesenchymal transition by targeting MRTF-A. Figure 7 . miR-219a-5p inhibits breast cancer cell migration and EMT by targeting MRTF-A miR-219a-5p mimics, MRTF-A overexpression plasmid, or both of them were transfected into breast cancer MDA-MB-231 cells, and then the expression of vimentin, N-cadherin and E-cadherin was detected by real-time PCR (A) and western blot analysis (B). pcDNA3.1 was the empty vector control. The cellular migratory ability was measured by wound-healing assay (C) and transwell assay (D). *P < 0.05, **P < 0.01. Experiments were repeated three times (n = 3).
Inhibition of miR-219a-5p increases EMT in MCF-7 cells
miR-219a-5p inhibitor was transfected into MCF-7 cells, and then the expression of mesenchymal markers and epithelial marker were detected by real-time PCR and western blot analysis (Fig. 8A,B) . N-cadherin and vimentin were dramatically up-regulated in MCF-7 cells transfected with miR-219a-5p inhibitor, while E-cadherin, epithelial marker, was down-regulated. These results confirmed that anti-miR-219a-5p could increase EMT in MCF-7 cells.
Discussion
It has been reported that miR-219a-5p inhibits glioblastoma cell and papillary thyroid carcinoma (PTC) cell migration, and downregulation of miR219 is associated with metastatic prostate cancer [34] [35] [36] [37] . miR-219-5p may function as a tumor suppressor by decreasing calcyphosine (CAGE), and subsequently inhibit tumor proliferation. However, whether miR-219a-5p can inhibit breast cancer cell migration is unclear. In this study, we demonstrated that miR-219a-5p could inhibit MDA-MB-231 cell migration, and also inhibit EMT progress of MDA-MB-231 cells.
The EMT is a biological process in which a non-motile epithelial cell changes to a mesenchymal state with invasive capacities. However, the EMT program is involved in both physiological and pathological processes. Cancer-associated EMT is known to contribute to increase invasiveness and metastasis, resistance to therapies, and generation of cell populations with stem cell-like characteristics. Therefore it is deeply involved in tumor progression.
It has been reported that many miRNAs are closely related to the occurrence of breast cancer. In the MCF-7 cells, miR-410-3p inhibites EMT [38] . microRNA-497 modulates breast cancer cell proliferation and survival by targeting SMAD7 [39] . miR-10b and miR-181b-3p induce EMT in MCF-7 breast cancer cells. miR-181b-3p promotes EMT in breast cancer cells through Snail stabilization by directly targeting YWHAG [40] . miR-487a promotes TGF-β1-induced EMT and the migration of T47D cells and MCF-7 cells by directly targeting MAGI2 [41] . In MDA-MB-231 cells, miRNA-21 induces EMT via the phosphatase and tensin homolog deleted on protein tyrosine phosphatase/frotein kinase B (PTEN/AKT) pathway, while miR-671-5p inhibits EMT by downregulating forkhead box protein M1 (FOXM1) expression in MDA-MB-231 cells. MicroRNA-195 inhibits proliferation and metastasis in MCF-7 cells and MDA-MB-231 cells by targeting fatty acid synthase (FASN), HMG-CoA reductase (HMGCR), acetyl-CoA carboxylase 1 (ACACA), and cytochrome P450VD1-alpha 27B1 (CYP27B1) [42] . miR-204-5p could suppress the migration of breast cancer cell lines. microRNA-219-5p was reported to carry out its function by targeting roundabout homolog 1 (ROBO1) [35] and EGFR [20] in glioblastoma cells. In this study, we identified a new target gene of miR-219a-5p, MRTF-A. Our data showed that miR-219a-5p mimics inhibited the transcription and expression of MRTF-A by targeting the 3′UTR of MRTF-A. Our previous studies showed that MRTF-A can promote the migration of breast cancer MCF-7 and MDA-MB-231 cells by up-regulating myosin regulatory light polypeptide 9 (MYL-9), myosin heavy chain 9 (MYH-9) and cysteine-rich angiogenic inducer 61 (CYR61) [43, 44] . Furthermore, our data confirmed that MRTF-A could promote EMT in MDA-MB-231 cells by increasing mesenchymal marker vimentin expression and decreasing epithelial marker Ecadherin expression. It has been reported that MRTF-A plays an important role in EMT of multiple kinds of epithelial cells [45] [46] [47] .
In summary, in this study we set up a simple EMT-MET model in MCF-7 cells via the addition and removal of TGF-β and revealed the tumor suppressive role of miR-219a-5p in regulating breast cancer migration. Our results suggested that miR-219a-5p might be a therapeutic target in breast cancer through regulating EMT. We also identified a new target gene of miR-219a-5p, MRTF-A, and confirmed the essential role of MRTF-A in breast cancer cell migration and EMT. Figure 8 . Inhibition of miR-219a-5p increases EMT in MCF-7 cells miR-219a-5p inhibitor was transfected into MCF-7 cells, and then the expression of vimentin, N-cadherin and E-cadherin were detected by real-time PCR (A) and western blot analysis (B). **P < 0.01. Experiments were repeated three times (n = 3).
